TNSN00112A1 - Suspensions de ziprasidone nouvelles et procede pour leur preparation. - Google Patents

Suspensions de ziprasidone nouvelles et procede pour leur preparation.

Info

Publication number
TNSN00112A1
TNSN00112A1 TNTNSN00112A TNSN00112A TNSN00112A1 TN SN00112 A1 TNSN00112 A1 TN SN00112A1 TN TNSN00112 A TNTNSN00112 A TN TNSN00112A TN SN00112 A TNSN00112 A TN SN00112A TN SN00112 A1 TNSN00112 A1 TN SN00112A1
Authority
TN
Tunisia
Prior art keywords
ziprasidone
preparation
suspensions
new
compositions
Prior art date
Application number
TNTNSN00112A
Other languages
English (en)
Inventor
Ray Arenson Daniel
Qi Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN00112(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN00112A1 publication Critical patent/TNSN00112A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Dental Preparations (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)

Abstract

L’INVENTION CONCERNE DES COMPOSITIONS COMPRENANT DE LA ZIPRASIDONE SOUS FORME DE BASE LIBRE OU UN SEL D’ADDITION D’ACIDE DE ZIPRASIDONE DIFFICILE A MOUILLER, PHARMACEUTIQUEMENT ACCEPTABLE, UN POLYSORBATE ET DU DIOXYDE DE SILICIUM COLLOIDAL, FORMANT DES SUSPENSIONS AQUEUSES AVANTAGEUSES. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION. APPLICATION : UTILISATION DE CES COMPOSITIONS POUR LE TRAITEMENT DE PSYCHOSES.
TNTNSN00112A 1999-05-27 2000-05-24 Suspensions de ziprasidone nouvelles et procede pour leur preparation. TNSN00112A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
TNSN00112A1 true TNSN00112A1 (fr) 2005-11-10

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00112A TNSN00112A1 (fr) 1999-05-27 2000-05-24 Suspensions de ziprasidone nouvelles et procede pour leur preparation.

Country Status (50)

Country Link
EP (1) EP1181018B1 (fr)
JP (1) JP3942827B2 (fr)
KR (1) KR100477782B1 (fr)
CN (1) CN1196486C (fr)
AP (1) AP1409A (fr)
AR (1) AR022643A1 (fr)
AT (1) ATE234097T1 (fr)
AU (1) AU777413B2 (fr)
BG (1) BG65367B1 (fr)
BR (1) BR0010990A (fr)
CA (1) CA2371550C (fr)
CO (1) CO5170458A1 (fr)
CR (1) CR6506A (fr)
CU (1) CU23223B7 (fr)
CZ (1) CZ20014230A3 (fr)
DE (1) DE60001649T2 (fr)
DK (1) DK1181018T3 (fr)
DZ (1) DZ3049A1 (fr)
EA (1) EA003907B1 (fr)
EE (1) EE04704B1 (fr)
ES (1) ES2191618T3 (fr)
GC (1) GC0000190A (fr)
GE (1) GEP20033113B (fr)
GT (1) GT200000081A (fr)
HK (1) HK1046366B (fr)
HN (1) HN2000000071A (fr)
HR (1) HRP20010878B1 (fr)
HU (1) HUP0201297A3 (fr)
IL (2) IL145950A0 (fr)
IS (1) IS2396B (fr)
MA (1) MA26741A1 (fr)
MX (1) MXPA01012124A (fr)
MY (1) MY127891A (fr)
NO (1) NO320296B1 (fr)
NZ (1) NZ514764A (fr)
OA (1) OA11946A (fr)
PA (1) PA8495801A1 (fr)
PE (1) PE20010127A1 (fr)
PL (1) PL196867B1 (fr)
RS (1) RS50089B (fr)
SI (1) SI1181018T1 (fr)
SK (1) SK284590B6 (fr)
SV (1) SV2001000085A (fr)
TN (1) TNSN00112A1 (fr)
TR (1) TR200103392T2 (fr)
TW (1) TWI263498B (fr)
UA (1) UA59491C2 (fr)
UY (1) UY26166A1 (fr)
WO (1) WO2000072847A1 (fr)
ZA (1) ZA200109692B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
CN100337630C (zh) * 2002-03-12 2007-09-19 布里斯托尔-迈尔斯斯奎布公司 可口的口服悬浮液及其制备方法
WO2004037224A1 (fr) * 2002-10-25 2004-05-06 Pfizer Products Inc. Formulations de depot d'agents actifs arylheterocycliques sous forme de suspension
WO2004037289A2 (fr) * 2002-10-25 2004-05-06 Pfizer Products Inc. Nouvelles formulations de depot injectables
EP1418492B1 (fr) 2002-11-05 2017-09-20 LG Electronics, Inc. Assemblage pour le montage d'un écran tactile pour un affichage à cristaux liquides
WO2005040160A2 (fr) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Procedes de preparation de ziprasidone
WO2005107719A2 (fr) 2004-05-06 2005-11-17 Sandoz Ag Composition pharmaceutique comprenant un medicament hydrophobe a solubilite amelioree
WO2005123086A2 (fr) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Forme de dosage de ziprasidone
WO2006085168A2 (fr) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Formes de dosage orales solides de ziprasidone
CA2613474A1 (fr) * 2005-06-20 2007-03-08 Elan Pharma International Limited Compositions de nanoparticules a liberation controlee comprenant des composes d'aryle heterocyclique
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
DE60001649T2 (de) 2003-08-21
GT200000081A (es) 2001-11-16
CA2371550C (fr) 2007-01-02
GEP20033113B (en) 2003-11-25
EP1181018A1 (fr) 2002-02-27
AU4138500A (en) 2000-12-18
DE60001649D1 (de) 2003-04-17
ATE234097T1 (de) 2003-03-15
HRP20010878B1 (en) 2007-03-31
BG65367B1 (bg) 2008-04-30
SV2001000085A (es) 2001-11-08
IS2396B (is) 2008-08-15
TWI263498B (en) 2006-10-11
HUP0201297A2 (en) 2002-08-28
OA11946A (en) 2006-04-13
BG106153A (bg) 2002-06-28
CR6506A (es) 2004-03-24
CZ20014230A3 (cs) 2002-08-14
DZ3049A1 (fr) 2004-03-27
BR0010990A (pt) 2002-03-05
CN1196486C (zh) 2005-04-13
DK1181018T3 (da) 2003-04-22
EE04704B1 (et) 2006-10-16
MY127891A (en) 2006-12-29
AR022643A1 (es) 2002-09-04
PL352826A1 (en) 2003-09-08
EA200101131A1 (ru) 2002-04-25
HN2000000071A (es) 2001-02-02
IL145950A (en) 2007-12-03
PL196867B1 (pl) 2008-02-29
JP2003500449A (ja) 2003-01-07
NZ514764A (en) 2004-04-30
HK1046366A1 (en) 2003-01-10
EP1181018B1 (fr) 2003-03-12
RS50089B (sr) 2009-01-22
NO20015755L (no) 2002-01-23
YU76701A (sh) 2005-07-19
AU777413B2 (en) 2004-10-14
MXPA01012124A (es) 2002-06-04
ES2191618T3 (es) 2003-09-16
UA59491C2 (uk) 2003-09-15
TR200103392T2 (tr) 2002-11-21
CN1352560A (zh) 2002-06-05
GC0000190A (en) 2006-03-29
EE200100633A (et) 2003-02-17
PA8495801A1 (es) 2001-12-14
SK16782001A3 (sk) 2002-09-10
HK1046366B (zh) 2005-07-29
SI1181018T1 (en) 2003-06-30
CU23223B7 (es) 2007-08-30
ZA200109692B (en) 2002-11-26
PE20010127A1 (es) 2001-02-06
KR20020048307A (ko) 2002-06-22
CA2371550A1 (fr) 2000-12-07
IS6134A (is) 2001-10-30
HUP0201297A3 (en) 2005-09-28
HRP20010878A2 (en) 2003-06-30
MA26741A1 (fr) 2004-12-20
NO20015755D0 (no) 2001-11-26
JP3942827B2 (ja) 2007-07-11
AP1409A (en) 2005-06-13
UY26166A1 (es) 2000-12-29
SK284590B6 (sk) 2005-07-01
IL145950A0 (en) 2002-07-25
AP2001002346A0 (en) 2001-12-31
CO5170458A1 (es) 2002-06-27
WO2000072847A1 (fr) 2000-12-07
KR100477782B1 (ko) 2005-03-21
NO320296B1 (no) 2005-11-21
EA003907B1 (ru) 2003-10-30

Similar Documents

Publication Publication Date Title
TNSN00112A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
YU83502A (sh) Nova farmaceutska smeša
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
DE69940769D1 (de) Orale flüssige zusammensetzungen
MA26914A1 (fr) Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale
TNSN00028A1 (fr) Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant
TNSN99079A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98127A1 (fr) Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
TNSN99007A1 (fr) Composition de mesylate de trovafloxacine et procede pour sa preparation
SE0104331D0 (sv) Novel compounds
TNSN98185A1 (fr) Derives d'isoquinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00106A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
TNSN99056A1 (fr) Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant